These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 23470679)

  • 1. Outcomes of children with enterobacteriaceae bacteremia with reduced susceptibility to ceftriaxone: do the revised breakpoints translate to improved patient outcomes?
    Tamma PD; Wu H; Gerber JS; Hsu AJ; Tekle T; Carroll KC; Cosgrove SE
    Pediatr Infect Dis J; 2013 Sep; 32(9):965-9. PubMed ID: 23470679
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Empirical third-generation cephalosporin therapy for adults with community-onset Enterobacteriaceae bacteraemia: Impact of revised CLSI breakpoints.
    Hsieh CC; Lee CH; Li MC; Hong MY; Chi CH; Lee CC
    Int J Antimicrob Agents; 2016 Apr; 47(4):297-303. PubMed ID: 27005458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enterobacteriaceae Sepsis Outcome Programme annual report, 2013.
    Turnidge JD; Gottlieb T; Mitchell DH; Coombs GW; Daly DA; Bell JM;
    Commun Dis Intell Q Rep; 2014 Dec; 38(4):E327-33. PubMed ID: 25631595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of mortality stratified by meropenem minimum inhibitory concentration in patients with Enterobacteriaceae bacteraemia: A patient-level analysis of published data.
    O'Donnell JN; Rhodes NJ; Biehle LR; Esterly JS; Patel TS; McLaughlin MM; Hirsch EB
    Int J Antimicrob Agents; 2020 Feb; 55(2):105849. PubMed ID: 31770628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of revised CLSI breakpoints for susceptibility to third-generation cephalosporins and carbapenems among Enterobacteriaceae isolates in the Asia-Pacific region: results from the Study for Monitoring Antimicrobial Resistance Trends (SMART), 2002-2010.
    Huang CC; Chen YS; Toh HS; Lee YL; Liu YM; Ho CM; Lu PL; Liu CE; Chen YH; Wang JH; Tang HJ; Yu KW; Liu YC; Chuang YC; Xu Y; Ni Y; Ko WC; Hsueh PR
    Int J Antimicrob Agents; 2012 Jun; 40 Suppl():S4-10. PubMed ID: 22749058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of European Committee on Antimicrobial Susceptibility Testing (EUCAST) and CLSI screening parameters for the detection of extended-spectrum β-lactamase production in clinical Enterobacteriaceae isolates.
    Polsfuss S; Bloemberg GV; Giger J; Meyer V; Hombach M
    J Antimicrob Chemother; 2012 Jan; 67(1):159-66. PubMed ID: 21972269
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Empiric Monotherapy Versus Combination Therapy for Enterobacteriaceae Bacteremia in Children.
    Berkowitz NM; Spaeder MC; DeBiasi RL; Campos J; Singh N
    Pediatr Infect Dis J; 2015 Nov; 34(11):1203-6. PubMed ID: 26301498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reevaluation of Enterobacteriaceae MIC/disk diffusion zone diameter regression scattergrams for 9 beta-lactams: adjustments of breakpoints for strains producing extended spectrum beta-lactamases.
    Jones RN; Craig WA; Ambrose PG; Dudley MN; Pottumarthy S
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):235-46. PubMed ID: 16105568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of revised CLSI cefazolin breakpoints on the clinical outcomes of Escherichia coli bacteremia.
    Wang KC; Liu MF; Lin CF; Shi ZY
    J Microbiol Immunol Infect; 2016 Oct; 49(5):768-774. PubMed ID: 26493889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cefepime therapy for monomicrobial bacteremia caused by cefepime-susceptible extended-spectrum beta-lactamase-producing Enterobacteriaceae: MIC matters.
    Lee NY; Lee CC; Huang WH; Tsui KC; Hsueh PR; Ko WC
    Clin Infect Dis; 2013 Feb; 56(4):488-95. PubMed ID: 23090931
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Outcomes in Patients With Gram-Negative Infections Treated With Optimized Dosing Cefepime Over Various Minimum Inhibitory Concentrations.
    Altshuler J; Guervil DJ; Ericsson CD; Wanger A; Aitken SL; Ostrosky-Zeichner L
    J Pharm Pract; 2018 Feb; 31(1):34-39. PubMed ID: 29278990
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MIC of amoxicillin/clavulanate according to CLSI and EUCAST: discrepancies and clinical impact in patients with bloodstream infections due to Enterobacteriaceae.
    Delgado-Valverde M; Valiente-Mendez A; Torres E; Almirante B; Gómez-Zorrilla S; Borrell N; Aller-García AI; Gurgui M; Almela M; Sanz M; Bou G; Martínez-Martínez L; Cantón R; Antonio Lepe J; Causse M; Gutiérrez-Gutiérrez B; Pascual Á; Rodríguez-Baño J;
    J Antimicrob Chemother; 2017 May; 72(5):1478-1487. PubMed ID: 28093484
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antimicrobial resistance to cefotaxime and ertapenem in Enterobacteriaceae: the effects of altering clinical breakpoints.
    Liu PY; Shi ZY; Tung KC; Shyu CL; Chan KW; Liu JW; Wu ZY; Kao CC; Huang YC; Lin CF
    J Infect Dev Ctries; 2014 Mar; 8(3):289-96. PubMed ID: 24619258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of borderline minimum inhibitory concentration on the outcome of invasive infections caused by Enterobacteriaceae treated with β-lactams: a systematic review and meta-analysis.
    Torres E; Delgado M; Valiente A; Pascual Á; Rodríguez-Baño J
    Eur J Clin Microbiol Infect Dis; 2015 Sep; 34(9):1751-8. PubMed ID: 26032669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment.
    Tumbarello M; Sanguinetti M; Montuori E; Trecarichi EM; Posteraro B; Fiori B; Citton R; D'Inzeo T; Fadda G; Cauda R; Spanu T
    Antimicrob Agents Chemother; 2007 Jun; 51(6):1987-94. PubMed ID: 17387156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Can the Ceftriaxone Breakpoints Be Increased Without Compromising Patient Outcomes?
    Tamma PD; Pierce VM; Cosgrove SE; Lautenbach E; Harris A; Rayapati D; Han JH
    Open Forum Infect Dis; 2018 Jun; 5(6):ofy139. PubMed ID: 29992175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of revised susceptibility breakpoints on bacteremia of Klebsiella pneumoniae: Minimum inhibitory concentration of cefazolin and clinical outcomes.
    Chuang CH; Liu MF; Lin CF; Shi ZY
    J Microbiol Immunol Infect; 2016 Oct; 49(5):679-684. PubMed ID: 25442869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does the piperacillin minimum inhibitory concentration for Pseudomonas aeruginosa influence clinical outcomes of children with pseudomonal bacteremia?
    Tamma PD; Turnbull AE; Milstone AM; Hsu AJ; Carroll KC; Cosgrove SE
    Clin Infect Dis; 2012 Sep; 55(6):799-806. PubMed ID: 22696019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Commentary: revised susceptibility breakpoints: fear, loathing and good science.
    Dudley MN; Ambrose PG; Jones RN
    Pediatr Infect Dis J; 2013 Sep; 32(9):970-1. PubMed ID: 24008738
    [No Abstract]   [Full Text] [Related]  

  • 20. Breakpoints for intravenously used cephalosporins in Enterobacteriaceae--EUCAST and CLSI breakpoints.
    Kahlmeter G
    Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():169-74. PubMed ID: 18154542
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.